advanced search
Dr Andreas Bilstein
Managing Director
URSATEC

Is this your profile?

About

Andreas Bilstein, PhD, has been Managing Director of URSATEC since August 2020. He is a biologist and has more than 15 years of experience in developing preservative-free products for various applications.

Contributions

NASAL
CHALLENGES BESIDES DRUG TARGETING – REGULATORY HURDLES FOR MULTIDOSE NASAL SPRAYS
Marie-Christine Klein,  Andreas Bilstein and Rouven Kraus, discuss recent regulatory changes affecting drug-device combination products, using the example of a multidose nasal spray.

More contributions

PULMONARY
THE APPLICATION DIVERSITY OF METERED PUMP-BASED SOFT MIST DEVICES
Marie-Christine Klein, Andreas Bilstein and Caroline Hoffmann discuss the underlying techniques involved in the use of metered pump-based soft mist devices and their application diversity.
SKIN
“PRESERVATIVE FREE” – THE SKIN MICROBIOME’S CLOSE FRIEND
Marie-Christine Klein, Andreas Bilstein and Julia Krüger discuss the effects of preservatives on the skin microbiome and consider new technologies that minimise the percentage of preserving agents used in cosmetic formulations.
CONNECTIVITY
A GAME CHANGER FOR HIGH-RISK MEDICATIONS VIA AN INTRANASAL DELIVERY PLATFORM
Marcel Botha, Andreas Bilstein, Houssam Elghobary and Rouven Kraus discuss the benefits of the Validose digital health platform for the safe delivery of high-value and/or high-risk products.
NASAL
NOSE-TO-BRAIN DRUG ADMINISTRATION AND A NOVEL APPROACH WITH AN OLD FAMILIAR
Marie-Christine Klein, Andreas Bilstein and Rouven Kraus look at the advantages of the nose-to-brain route and soft mist nasal sprays for drug administration.
Top